Oral Viscous Budesonide Is Effective in Children With Eosinophilic Esophagitis in a Randomized, Placebo-Controlled Trial Ranjan Dohil, Robert Newbury,

Slides:

Advertisements

Similar presentations

Volume 152, Issue 5, Pages e1 (April 2017)

Advertisements

Volume 148, Issue 2, Pages e5 (February 2015)

The Value of a 24/7 Online Nationwide Multidisciplinary Expert Panel for Acute Necrotizing Pancreatitis Janneke van Grinsven, Sandra van Brunschot Gastroenterology

Volume 135, Issue 5, Pages (November 2008)

Another Earth: Innate Lymphoid Cells and Intestinal Inflammation

Volume 139, Issue 6, Pages e2 (December 2010)

Volume 147, Issue 3, Pages (September 2014)

Volume 147, Issue 2, Pages e5 (August 2014)

Amir F. Kagalwalla, Joshua B

The Value of a 24/7 Online Nationwide Multidisciplinary Expert Panel for Acute Necrotizing Pancreatitis Janneke van Grinsven, Sandra van Brunschot Gastroenterology

Volume 148, Issue 2, Pages e5 (February 2015)

Volume 154, Issue 5, Pages e3 (April 2018)

Diagnosis and Management of Eosinophilic Esophagitis

Volume 133, Issue 5, Pages (November 2007)

A Patient With Left Upper Abdominal Pain Who Had Petit Sac

Volume 137, Issue 5, Pages (November 2009)

Volume 149, Issue 2, Pages e3 (August 2015)

Ira J. Fox, Stephen C. Strom Gastroenterology

Comparison of Oral Prednisone and Topical Fluticasone in the Treatment of Eosinophilic Esophagitis: A Randomized Trial in Children Elizabeth T. Schaefer,

Intragastric pH With Oral vs Intravenous Bolus Plus Infusion Proton-Pump Inhibitor Therapy in Patients With Bleeding Ulcers Loren Laine, Abbid Shah,

Volume 154, Issue 4, Pages e1 (March 2018)

Clinical Challenges and Images in GI

Volume 131, Issue 5, Pages (November 2006)

Unusual Case of an Upset Stomach

Volume 153, Issue 3, Pages e16-e17 (September 2017)

Management of Patients With Functional Heartburn

Volume 150, Issue 4, Pages (April 2016)

Metoclopramide Nasal Spray Reduces Symptoms of Gastroparesis in Women, but not Men, With Diabetes: Results of a Phase 2B Randomized Study Henry P. Parkman,

Volume 137, Issue 2, Pages (August 2009)

Safety and Efficacy of Budesonide Oral Suspension Maintenance Therapy in Patients With Eosinophilic Esophagitis Evan S. Dellon, David A. Katzka, Margaret.

Optimal Histologic Cutpoints for Treatment Response in Patients With Eosinophilic Esophagitis: Analysis of Data From a Prospective Cohort Study Craig.

Volume 137, Issue 1, Pages (July 2009)

Microscopic Esophageal Mucosal Injury in Nonerosive Reflux Disease

Advances in Clinical Management of Eosinophilic Esophagitis

Volume 141, Issue 1, Pages e1 (July 2011)

Swallowed Fluticasone Improves Histologic but Not Symptomatic Response of Adults With Eosinophilic Esophagitis Jeffrey A. Alexander, Kee Wook Jung, Amindra.

Chan Wah Kheong, Nik Raihan Nik Mustapha, Sanjiv Mahadeva

Laura Rotundo, Sushil Ahlawat Gastroenterology

Renee Rawson, BS, Tom Yang, BS, Robert O

Targeting Smads to Restore Transforming Growth Factor-β Signaling and Regulatory T- Cell Function in Inflammatory Bowel Disease Deanna D. Nguyen, Scott.

Seema S. Aceves Clinical Gastroenterology and Hepatology

Volume 152, Issue 4, Pages e5 (March 2017)

Microscopic Esophageal Mucosal Injury in Nonerosive Reflux Disease

A Selection of the Best AGA Abstracts of DDW 2017

Volume 149, Issue 1, Pages e6 (July 2015)

Clinical Gastroenterology and Hepatology

Volume 153, Issue 4, Pages (October 2017)

Volume 141, Issue 5, Pages (November 2011)

Proton Pump Inhibitors Partially Restore Mucosal Integrity in Patients With Proton Pump Inhibitor–Responsive Esophageal Eosinophilia but Not Eosinophilic.

Amer A. Alkhatib, MD, Rodney W. Stuart, MD, Ronald L. Weiss, MD

Volume 150, Issue 7, Pages (June 2016)

Volume 142, Issue 7, Pages e1 (June 2012)

Secondary Prophylaxis of Hepatic Encephalopathy: An Open-Label Randomized Controlled Trial of Lactulose Versus Placebo Barjesh Chander Sharma, Praveen.

Volume 156, Issue 1, Pages 7-10 (January 2019)

Siddharth Singh, Matthew T. Howard, Konstantinos A. Papadakis

Volume 134, Issue 5, Pages (May 2008)

TGF-β1–induced phospholamban expression alters esophageal smooth muscle cell contraction in patients with eosinophilic esophagitis Lisa Y. Beppu, BS,

Volume 139, Issue 6, Pages e1 (December 2010)

Morphogens and the Parietal Cell: Shaping Up Acid Secretion

Eosinophilic esophagitis treated with immunotherapy to dust mites

Volume 153, Issue 3, Pages e2 (September 2017)

Anti–IL-5 therapy reduces mast cell and IL-9 cell numbers in pediatric patients with eosinophilic esophagitis Iris M. Otani, MD, Arjun A. Anilkumar,

Electronic Clinical Challenges and Images in GI

Volume 139, Issue 6, Pages e2 (December 2010)

Covering the Cover Gastroenterology

Volume 157, Issue 1, Pages e5 (July 2019)

Unrelenting Abdominal Pain after Recent Initiation of a Direct Oral Anticoagulant: A Cause for Concern Nicholas R. Crews, Nabil Fayad Gastroenterology

Mast cells infiltrate the esophageal smooth muscle in patients with eosinophilic esophagitis, express TGF-β1, and increase esophageal smooth muscle contraction

Abnormal Gastrointestinal Imaging in a Patient With Dyspepsia

Volume 157, Issue 1, Pages (July 2019)

Presentation transcript:

Oral Viscous Budesonide Is Effective in Children With Eosinophilic Esophagitis in a Randomized, Placebo-Controlled Trial Ranjan Dohil, Robert Newbury, Lyman Fox, John Bastian, Seema Aceves Gastroenterology Volume 139, Issue 2, Pages 418-429.e1 (August 2010) DOI: 10.1053/j.gastro.2010.05.001 Copyright © 2010 AGA Institute Terms and Conditions

Figure 1 Individual pre- and post-treatment peak eosinophil (Eos) counts following 3 months' treatment with OVB and PPI (n = 15) and placebo plus PPI (n = 9). HPF, high-powered field; Tx, treatment. Gastroenterology 2010 139, 418-429.e1DOI: (10.1053/j.gastro.2010.05.001) Copyright © 2010 AGA Institute Terms and Conditions

Figure 2 Mean symptom scores during months 1, 2, and 3 of the study for patients in the OVB and placebo groups. Comparing changes from baseline, the mean symptom score improved significantly in the OVB group during months 1, 2, and 3, but not in the placebo group. Gastroenterology 2010 139, 418-429.e1DOI: (10.1053/j.gastro.2010.05.001) Copyright © 2010 AGA Institute Terms and Conditions

Figure 3 (A) Pretreatment distal esophageal mucosal biopsy. Above left, showing several intraepithelial eosinophils, basal zone hyperplasia, and intercellular edema (H&E ×200). Above right, lamina propria with fibrosis and eosinophilic inflammation (H&E ×400). (B) Post-treatment with OVB, distal esophageal biopsy from the same patient. Above left, unremarkable epithelium (H&E ×100). Above right shows lamina propria with no evidence of fibrosis or eosinophilic inflammation (H&E ×400). (C) Esophageal mucosal biopsies (×400 light microscopy) stained for profibrotic mediators showing LP in a responder patient. Upper images show transforming growth factor–β1 (TGFβ1)-positive (brown) cells and lower images show phosphorylated Smad2/3-positive (red) cells pre- and post-treatment with OVB. Gastroenterology 2010 139, 418-429.e1DOI: (10.1053/j.gastro.2010.05.001) Copyright © 2010 AGA Institute Terms and Conditions

Supplementary Figure 1 Flow diagram showing study patients. Gastroenterology 2010 139, 418-429.e1DOI: (10.1053/j.gastro.2010.05.001) Copyright © 2010 AGA Institute Terms and Conditions